CSCharles D. Stiles

Charles D. Stiles

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charles D. Stiles has a total of 122 co-authors. Here are the top co-authors by number of shared publications:

  • John A. Alberta

    Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

    9 shared publications
  • David H. Rowitch

    Department of Paediatrics, University of Cambridge, Cambridge, UK

    8 shared publications
  • Keith L. Ligon

    Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

    5 shared publications
  • Michael F. Kane

    Department of Neurobiology, Harvard Medical School and Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215

    4 shared publications
  • Shwetal Mehta

    Departments of Neurobiology, Harvard Medical School and Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA

    4 shared publications
  • Dimphna H. Meijer

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States

    3 shared publications

Latest Publications

  • Population Control: Cortical Interneurons Modulate Oligodendrogenesis

    by Pratiti Bandopadhayay, Charles D. Stiles


  • Open Access

    A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2

    by Jing Zhou, An-Chi Tien, John A. Alberta, Scott B. Ficarro, Amelie Griveau, Yu Sun, Janhavee S. Deshpande, Joseph D. Card, Meghan Morgan-Smith, Wojciech Michowski, et al.


  • Open Access

    A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas

    by Yu Sun, John A. Alberta, Catherine Pilarz, David Calligaris, Emily J. Chadwick, Shakti H. Ramkissoon, Lori A. Ramkissoon, Veronica Matia Garcia, Emanuele Mazzola, Liliana Goumnerova, et al.

    Activating mutations or structural rearrangements in BRAF are identified in roughly 75% of all pediatric low-grade astrocytomas (PLGAs). However, first-generation RAF inhibitors approved for adult melanoma have poor blood–brain penetrance and are only effective on tumors that express the canonical BRAFV600E oncoprotein, which functions as a monomer. These drugs (type I antagonists that target the “DFG-in” conformation of the kinase) fail to block signaling via KIAA1549:BRAF, a truncation/fusion BRAF oncoprotein which functions as a dimer and is found in the most common form of PLGA. A panel of small molecule RAF inhibitors (including type II inhibitors, targeting the “DFG-out” conformation of the kinase) was screened for drugs showing efficacy on murine models of PLGA and on authentic human PLGA cells expressing KIAA1549:BRAF. We identify a type II RAF inhibitor that serves as an equipotent antagonist of BRAFV600E, KIAA1549:BRAF, and other noncanonical BRAF oncoproteins that function as dimers. This drug (MLN2480, also known as TAK-580) has good brain penetrance and is active on authentic human PLGA cells in brain organotypic cultures. MLN2480 may be an effective therapeutic for BRAF mutant pediatric astrocytomas.


  • Challenges in Targeting a Basic Helix–Loop–Helix Transcription Factor with Hydrocarbon-Stapled Peptides

    by Amanda L. Edwards, Dimphna H. Meijer, Rachel M. Guerra, Remco J. Molenaar, John A. Alberta, Federico Bernal, Gregory H. Bird, Charles D. Stiles, Loren D. Walensky

    Basic helix–loop–helix (bHLH) transcription factors play critical roles in organism development and disease by regulating cell proliferation and differentiation. Transcriptional activity, whether by bHLH homo- or heterodimerization, is dependent on protein–protein and protein–DNA interactions mediated by α-helices. Thus, α-helical decoys have been proposed as potential targeted therapies for pathologic bHLH transcription. Here, we developed a library of stabilized α-helices of OLIG2 (SAH-OLIG2) to test the capacity of hydrocarbon-stapled peptides to disrupt OLIG2 homodimerization, which drives the development and chemoresistance of glioblastoma multiforme, one of the deadliest forms of human brain cancer. Although stapling successfully reinforced the α-helical structure of bHLH constructs of varying length, sequence-specific dissociation of OLIG2 dimers from DNA was not achieved. Re-evaluation of the binding determinants for OLIG2 self-association and stability revealed an unanticipated role of the C-terminal domain. These data highlight potential pitfalls in peptide-based targeting of bHLH transcription factors given the liabilities of their positively charged amino acid sequences and multifactorial binding determinants.


  • Pathology and Molecular Pathology of Brain Cancer

    by Keith L. Ligon, Kim Wilkinson, Charles D. Stiles


  • Open Access

    Gliomas "Dope Up" for Growth.

    by Brenton R. Paolella, Charles D. Stiles


  • Open Access

    Of Brains and Blood: Developmental Origins of Glioma Diversity?

    by Mariella G. Filbin, Charles D. Stiles


  • Open Access

    An Amino Terminal Phosphorylation Motif Regulates Intranuclear Compartmentalization of Olig2 in Neural Progenitor Cells

    by Dimphna H. Meijer, Y. Sun, Tao Liu, Michael F. Kane, John A. Alberta, Guillaume Adelmant, Robert Kupp, Jarrod A. Marto, David H. Rowitch, Yoshihiro Nakatani, et al.

    The bHLH transcription factor Olig2 is expressed in cycling neural progenitor cells but also in terminally differentiated, myelinating oligodendrocytes. Sustained expression of Olig2 is counterintuitive because all known functions of the protein in expansion of neural progenitors and specification of oligodendrocyte progenitors are completed with the formation of mature white matter. How are the biological functions of Olig2 suppressed in terminally differentiated oligodendrocytes? In previous studies, we have shown that a triple serine motif in the amino terminus of Olig2 is phosphorylated in cycling neural progenitors but not in their differentiated progeny. We now show that phosphorylation of the triple serine motif regulates intranuclear compartmentalization of murine Olig2. Phosphorylated Olig2 is preferentially localized to a transcriptionally active “open” chromatin compartment together with coregulator proteins essential for regulation of gene expression. Unphosphorylated Olig2, as seen in mature white matter, is localized mainly within a transcriptionally inactive, chromatin fraction characterized by condensed and inaccessible DNA. Of special note is the observation that the p53 tumor suppressor protein is confined to the open chromatin fraction. Proximity ligation assays show that phosphorylation brings Olig2 within 30 nm of p53 within the open chromatin compartment. The data thus shed light on previously noted promitogenic functions of phosphorylated Olig2, which reflect, at least in part, an oppositional relationship with p53 functions.


  • Open Access

    Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging

    by Xiaohui Liu, Jennifer L. Ide, Isaiah Norton, Mark A. Marchionni, Maritza C. Ebling, Lan Y. Wang, Erin Davis, Claire M. Sauvageot, Santosh Kesari, Katherine A. Kellersberger, et al.

    Drug transit through the blood-brain barrier (BBB) is essential for therapeutic responses in malignant glioma. Conventional methods for assessment of BBB penetrance require synthesis of isotopically labeled drug derivatives. Here, we report a new methodology using matrix assisted laser desorption ionization mass spectrometry imaging (MALDI MSI) to visualize drug penetration in brain tissue without molecular labeling. In studies summarized here, we first validate heme as a simple and robust MALDI MSI marker for the lumen of blood vessels in the brain. We go on to provide three examples of how MALDI MSI can provide chemical and biological insights into BBB penetrance and metabolism of small molecule signal transduction inhibitors in the brain – insights that would be difficult or impossible to extract by use of radiolabeled compounds.


  • Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2

    by Dimphna H. Meijer, Michael F. Kane, Shwetal Mehta, Hongye Liu, Emily Harrington, Christopher M. Taylor, Charles D. Stiles, David H. Rowitch

    Despite their structural similarities and seemingly coordinated expression patterns, oligodendrocyte transcription factor 1 (OLIG1) and OLIG2 have largely non-overlapping roles in CNS development, brain diseases and neural repair. Here, the authors review the molecular factors that may account for the divergent functions of these proteins. The basic helix–loop–helix transcription factors oligodendrocyte transcription factor 1 (OLIG1) and OLIG2 are structurally similar and, to a first approximation, coordinately expressed in the developing CNS and postnatal brain. Despite these similarities, it was apparent from early on after their discovery that OLIG1 and OLIG2 have non-overlapping developmental functions in patterning, neuron subtype specification and the formation of oligodendrocytes. Here, we summarize more recent insights into the separate roles of these transcription factors in the postnatal brain during repair processes and in neurological disease states, including multiple sclerosis and malignant glioma. We discuss how the unique functions of OLIG1 and OLIG2 may reflect their distinct genetic targets, co-regulator proteins and/or post-translational modifications.